Karo Healthcare has announced their acquisition of the rights to the OTC brand, Proctosedyl from Bayer. This allows the transfer of ownership to the OTC pharmaceutical Proctosedyl and exclusive license to their trademark in Italy, from Bayer to Karo.
This will expand Karo’s presence within Italy and continues their M&A ambitions of focusing on brands with strong equity.
Karo Healthcare were provided legal support by the team led by Stefano Giberti and Francesco Setti at Franzosi Dal Negro Setti which supported Karo throughout this acquisition.
